MNPR: Monopar Therapeutics Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 7 sales totaling $3.22M in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-01 | Starr Christopher M | Director | $362K | yes |
| 2026-10-01 | Starr Christopher M | Director | $234K | yes |
| 2026-10-01 | Starr Christopher M | Director | $64K | yes |
| 2026-09-24 | Robinson Chandler | CEO | $911K | yes |
| 2026-09-24 | Robinson Chandler | CEO | $848K | yes |
| 2026-09-24 | Robinson Chandler | CEO | $745K | yes |
| 2026-09-24 | Robinson Chandler | CEO | $54K | yes |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-12 | Fell below 5% | Adage Capital Management, L.P. | 4.76% | SEC |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.